This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Talon Therapeutics, Inc. Reports Fourth Quarter And Year End 2010 Financial Results

Additional information on Talon Therapeutics can be found at

The Talon Therapeutics, Inc. logo is available at

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include without limitation, statements regarding the timing of planned regulatory filings relating to Marqibo, Talon's ability to obtain accelerated approval of Marqibo for the treatment of Ph- adult ALL, and the potential of Marqibo to replace existing therapies. Such statements involve risks and uncertainties that could cause Talon's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Talon's clinical and regulatory development efforts relating to Marqibo will be successful; that even if an NDA for Marqibo is accepted by the FDA, that it will be approved; that the data of the clinical trials of Marqibo will be sufficient to support approval by the FDA of an NDA for Marqibo; that the results of the clinical trials of Marqibo will support Talon's claims or beliefs concerning Marqibo's safety and effectiveness; and that Talon will be able to secure the additional capital necessary to fund its product development programs, including Marqibo, to completion, Talon's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2010. Talon assumes no obligation to update these statements, except as required by law. 
  December 31, 2010 December 31, 2009
Current assets:    
Cash and cash equivalents $ 4,573,254 $ 9,570,453
Available-for-sale, equity securities 74,000 68,000
Available-for-sale, debt securities 17,993,745
Prepaid expenses and other current assets 253,901 114,067
Total current assets 22,894,900 9,752,520
Property and equipment, net 97,231 252,455
Restricted cash 125,000 125,000
Debt issuance costs 904,909 1,193,594
Total assets $ 24,022,040 $ 11,323,569
Current liabilities:    
Accounts payable and accrued liabilities $ 6,051,982 $ 4,027,075
Other short-term liabilities 1,787 43,586
Total current liabilities   6,053,769   4,070,661
Notes payable, net of discount 23,340,144 22,597,050
Other long-term liabilities 4,753 6,540
Investors' right to purchase future shares of Series A-1 and A-2 preferred stock 5,131,000
Warrant liabilities, non-current 712,965 2,145,511
Total long term liabilities 29,188,862 24,749,101
Total liabilities 35,242,631 28,819,762
Commitments and contingencies:    
Redeemable convertible preferred stock; $100 par value:    
10 million shares authorized, 0.4 million and 0 shares issued and outstanding at December 31, 2010 and December 31, 2009, respectively; aggregate liquidation value of $42.4 million and $0 at December 31, 2010 and December 31, 2009, respectively 30,643,219
Stockholders' deficit:    
Common stock; $0.001 par value:    
350 million and 200 million shares authorized, 21.2 million and 19.9 million shares issued and outstanding at December 31, 2010 and December 31, 2009, respectively 21,234 19,912
Additional paid-in capital 119,241,956 117,632,111
Accumulated other comprehensive loss (15,841) (24,000)
Accumulated deficit (161,111,159) (135,124,216)
Total stockholders' deficit (41,863,810) (17,496,193)
Total liabilities, redeemable convertible preferred stock and stockholders' deficit $ 24,022,040 $ 11,323,569
  Three Months Ended   December 31, Years Ended   December 31,
  2010 2009  2010 2009
  (unaudited) (unaudited)    
Operating expenses:        
General and administrative $ 1,270,891 $ 1,402,795 $ 5,570,820 $ 4,907,690
Research and development 5,228,110 3,990,944 20,194,878 14,692,417
Total operating expenses 6,499,001 5,393,729 25,765,698 19,600,097
Loss from operations (6,499,001) (5,393,729) (25,765,698) (19,600,097)
Other income (expense):        
Interest income 11,227 309 49,247 12,935
Interest expense (869,102) (946,750) (3,750,471) (3,442,893)
Other expense, net (3,512) (4,908)
Change in fair value of warrant liabilities (20,690) 1,345,554 (55,509) (1,103,666)
Change in fair value of investors' right to purchase future shares of Series A-1 and A-2 preferred stock 1,108,000 3,539,000
Total other income (expense) 229,434 399,113 (221,245) (4,538,532)
Net loss $ (6,269,567) $ (4,994,616) $ (25,986,943) $ (24,138,629)
Deemed dividends attributable to preferred stock (941,814) (32,308,787)
Net loss applicable to common stockholders (7,211,382) (4,994,616) (58,295,730) (24,138,629)
Net loss per share, basic and diluted $ (0.34) $ (0.28) $ (2.81) $ (2.27)
Weighted average shares used in computing net loss per share, basic and diluted 21,234,307 18,098,807 20,737,470 10,637,854
CONTACT: Talon Therapeutics, Inc.
         Investor & Media Contacts:
         Investor Relations Team
         (650) 588-6641

Talon Therapeutics, Inc. Logo

4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
GOOG $693.01 0.00%
FB $117.58 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs